Protalix BioTherapeutics, Inc. (PLX) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 5 Buy, 2 Hold.
Analysts estimate Earnings Per Share (EPS) of $0.02 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.04 vs est $0.02 (beat +166.7%). 2025: actual $-0.08 vs est $0.03 (missed -380.3%). Analyst accuracy: 1%.
PLX Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Protalix BioTherapeutics, Inc. in the past 3 months
EPS Estimates — PLX
1%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.04
vs Est $0.02
▲ 62.5% off
2025
Actual –$0.08
vs Est $0.03
▼ 135.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — PLX
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.053B
vs Est $0.054B
▼ 1.0% off
2025
Actual $0.053B
vs Est $0.062B
▼ 17.5% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
